DiaSorin (DSRLF) and Cytek Biosciences, Inc. (CTKB) announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging business unit to Cytek for approximately $46.5M. The decision to sell the FCI business unit to Cytek, announced on February 13, 2023, is in line with DiaSorin’s strategic priorities communicated to investors during the Capital Market Day in December 2021 to focus on the core for its future. The acquisition supports Cytek’s plan to develop new products and capabilities with FCI technology, expand its reach and offerings into customer segments previously underserved, and increase the efficiency of its operations.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CTKB:
- Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
- Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
- DiaSorin unit Luminex in pact with Cytek to sell FCI assets, no terms
- Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
- Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023